A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Completed · Phase 1

Conditions studied: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

In brief

This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.

Key facts

Study ID

NCT01121276

Run by

Novo Nordisk A/S

People needed

82

Starts

2010-04-01

Expected to finish

2010-09-01

Last updated by the study team

2017-01-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 1 or type 2 diabetes mellitus for more than 12 months
• Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for 12 months or longer for subjects with type 1 diabetes and for 3 months or longer for subjects with type 2 diabetes
• Body Mass Index (BMI) between 18.0-32.0 kg/m2 (both inclusive)

You may not qualify if…

• Surgery or trauma with significant blood loss (more than 500 mL) within the last 3 months prior to trial start
• Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
• Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

Where it is running

• Novo Nordisk Investigational Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.